Large-Cap Injectable-Focused Pharma Company Gains USFDA Nod for Key Pain Management Drug
Large-Cap Injectable-Focused Pharma Company Gains USFDA Nod for Key Pain Management Drug

Large-Cap Injectable-Focused Pharma Company Gains USFDA Nod for Key Pain Management Drug

With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent.

DSIJ Intelligence Article rating: 5.0

With a PE ratio of 36.6, the company trades at a premium compared to the industry PE of 36.4. The company has ROCE of 13.6 per cent and ROE of 9.26 per cent.

These quality mid-cap stocks have fallen more than 10 per cent in the month of December!
These quality mid-cap stocks have fallen more than 10 per cent in the month of December!

These quality mid-cap stocks have fallen more than 10 per cent in the month of December!

Amid the heavy sell off, many quality midcaps, which have proven to be wealth creators for the investors in the past, have witnessed correction and are trading at low PE

DSIJ Intelligence Article rating: 3.8

With times like these, investors shouldn’t panic and keep a close eye on the fundamentally strong companies,

Overnight Digest: Stocks to be kept an eye on May 5
Overnight Digest: Stocks to be kept an eye on May 5

Overnight Digest: Stocks to be kept an eye on May 5

India VIX zoomed 7.86 per cent at the end of Wednesday's trading session ending at 21.88.

DSIJ Intelligence Article rating: 4.3

On Wednesday, the domestic equity markets were driven majorly by events namely the commencement of the IPO of Life Insurance Corporation (LIC) and an increase of 40 bps in repo rate by Monetary Policy Committee (MPC).  

Overnight Digest: Stocks to keep an eye on April 22
Overnight Digest: Stocks to keep an eye on April 22

Overnight Digest: Stocks to keep an eye on April 22

DSIJ Intelligence Article rating: 4.5

On Thursday, the bulls took the charge and forced the benchmark indices to close on a higher note. The broader markets also replicated the benchmark indices and closed in green. 

RSS

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR